| Signatures of mutational processes in human cancer LB Alexandrov, S Nik-Zainal, DC Wedge, SAJR Aparicio, S Behjati, ... nature 500 (7463), 415-421, 2013 | 11236 | 2013 |
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy H Farmer, N McCabe, CJ Lord, ANJ Tutt, DA Johnson, TB Richardson, ... Nature 434 (7035), 917-921, 2005 | 8146 | 2005 |
| Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ... Annals of oncology 24 (9), 2206-2223, 2013 | 5058 | 2013 |
| Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers PC Fong, DS Boss, TA Yap, A Tutt, P Wu, M Mergui-Roelvink, P Mortimer, ... New England Journal of Medicine 361 (2), 123-134, 2009 | 4661 | 2009 |
| Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 3033* | 2020 |
| Landscape of somatic mutations in 560 breast cancer whole-genome sequences S Nik-Zainal, H Davies, J Staaf, M Ramakrishna, D Glodzik, X Zou, ... Nature 534 (7605), 47-54, 2016 | 2592 | 2016 |
| Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ... Annals of oncology 26 (8), 1533-1546, 2015 | 2525 | 2015 |
| Mutational processes molding the genomes of 21 breast cancers S Nik-Zainal, LB Alexandrov, DC Wedge, P Van Loo, CD Greenman, ... Cell 149 (5), 979-993, 2012 | 2326 | 2012 |
| Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial A Tutt, M Robson, JE Garber, SM Domchek, MW Audeh, JN Weitzel, ... The Lancet 376 (9737), 235-244, 2010 | 2298 | 2010 |
| Hallmarks of'BRCAness' in sporadic cancers N Turner, A Tutt, A Ashworth Nature reviews cancer 4 (10), 814-819, 2004 | 2073 | 2004 |
| The landscape of cancer genes and mutational processes in breast cancer PJ Stephens, PS Tarpey, H Davies, P Van Loo, C Greenman, DC Wedge, ... Nature 486 (7403), 400-404, 2012 | 2050 | 2012 |
| Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial MW Audeh, J Carmichael, RT Penson, M Friedlander, B Powell, ... The lancet 376 (9737), 245-251, 2010 | 1806 | 2010 |
| Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer ANJ Tutt, JE Garber, B Kaufman, G Viale, D Fumagalli, P Rastogi, ... New England Journal of Medicine 384 (25), 2394-2405, 2021 | 1772 | 2021 |
| The life history of 21 breast cancers S Nik-Zainal, P Van Loo, DC Wedge, LB Alexandrov, CD Greenman, ... Cell 149 (5), 994-1007, 2012 | 1749 | 2012 |
| Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition N McCabe, NC Turner, CJ Lord, K Kluzek, A Białkowska, S Swift, ... Cancer research 66 (16), 8109-8115, 2006 | 1581 | 2006 |
| De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ... Annals of Oncology 28 (8), 1700-1712, 2017 | 1463 | 2017 |
| Triple negative tumours: a critical review JS Reis‐Filho, ANJ Tutt Histopathology 52 (1), 108-118, 2008 | 1345 | 2008 |
| Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval PC Fong, TA Yap, DS Boss, CP Carden, M Mergui-Roelvink, C Gourley, ... Journal of clinical oncology 28 (15), 2512-2519, 2010 | 1214 | 2010 |
| Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials B Asselain, W Barlow, J Bartlett, J Bergh, E Bergsten-Nordström, J Bliss, ... The Lancet Oncology 19 (1), 27-39, 2018 | 1209 | 2018 |
| HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures H Davies, D Glodzik, S Morganella, LR Yates, J Staaf, X Zou, ... Nature medicine 23 (4), 517-525, 2017 | 1184 | 2017 |
